The main study objective is to observe the ability of the ITM block to provide clinically acceptable pain control after elective shoulder arthroscopy as measured by pain scores and morphine consumption.
The secondary objectives are determining its trajectory of efficacy up to 24 hours by measure of pain scores, morphine consumption and side effects.
Patients of any sex
Class ASAI-III
Patients 18 years of age or older
Scheduled for elective shoulder arthroscopy
Allergy to any of: ropivacaine, paracetamol, celecoxib, morphine, ondansetron or dexamethasone
Refusal or inability to give consent
Bleeding diathesis (according to HEMSTOP score)
Neurological deficit of the operative side
Single group
Infraspinatus-teres minor block
Other interventionA fascial plane block of the posterior shoulder with an injection between the infraspinatus and teres minor muscle which will anesthetise the axillary and supraclavicular nerves.
Analgesic efficacy
The binary primary endpoint is block success, requiring the two following criteria: 1. Early treatment success: defined as the absence of treatment failure during the initial 2 hours postoperatively. Treatment failure is defined as either the requirement for greater than or equal to 10 mg of intravenous morphine and a VAS pain score \>3, or a VAS pain score of greater than or equal to 7 at any time during this period. 2. Twenty-four-hour analgesic success: defined as a VAS pain score \<4 at 24 hours postoperatively while consuming no more than 30 mg of reserve oral morphine.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: